Shao X - Search Results

1

Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study.

Yuan Y, Wang Q, Ni Z, Che X, Cao L, Shao X, Zhang M, Xie Y, Qi C, Zhou W, Tian L, Mou S. Yuan Y, et al. Among authors: shao x. J Transl Med. 2015 Jun 6;13:186. doi: 10.1186/s12967-015-0549-2. J Transl Med. 2015. PMID: 26048044 Free PMC article.

2

Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells.

Wang Q, Shao X, Xu W, Qi C, Gu L, Ni Z, Mou S. Wang Q, et al. Among authors: shao x. Ren Fail. 2014 Apr;36(3):400-6. doi: 10.3109/0886022X.2013.867798. Epub 2014 Jan 7. Ren Fail. 2014. PMID: 24392874 Free article.

3

Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis.

Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, Ni Z, Mou S. Shao X, et al. PLoS One. 2014 Jan 3;9(1):e84131. doi: 10.1371/journal.pone.0084131. eCollection 2014. PLoS One. 2014. PMID: 24404151 Free PMC article.

4

Urinary excretion of liver-type FABP as a new clinical marker for the progression of obstructive nephropathy.

Xie Y, Xu W, Wang Q, Shao X, Ni Z, Mou S. Xie Y, et al. Among authors: shao x. Biomark Med. 2014;8(4):543-56. doi: 10.2217/bmm.13.136. Biomark Med. 2014. PMID: 24796620

5

Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro.

Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, Mou S, Ni Z. Xu W, et al. Among authors: shao x. J Pharmacol Exp Ther. 2014 Sep;350(3):552-62. doi: 10.1124/jpet.114.214205. Epub 2014 Jun 20. J Pharmacol Exp Ther. 2014. PMID: 24951279

6

Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.

Xie Y, Xue W, Shao X, Che X, Xu W, Ni Z, Mou S. Xie Y, et al. Among authors: shao x. PLoS One. 2014 Nov 17;9(11):e112865. doi: 10.1371/journal.pone.0112865. eCollection 2014. PLoS One. 2014. PMID: 25402279 Free PMC article.

7

L-FABP: A novel biomarker of kidney disease.

Xu Y, Xie Y, Shao X, Ni Z, Mou S. Xu Y, et al. Among authors: shao x. Clin Chim Acta. 2015 May 20;445:85-90. doi: 10.1016/j.cca.2015.03.017. Epub 2015 Mar 20. Clin Chim Acta. 2015. PMID: 25797895 Review.

8

The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up.

Tian L, Shao X, Xie Y, Wang L, Wang Q, Che X, Ni Z, Mou S. Tian L, et al. Among authors: shao x. Expert Opin Pharmacother. 2015 Jun;16(8):1137-47. doi: 10.1517/14656566.2015.1038238. Epub 2015 Apr 20. Expert Opin Pharmacother. 2015. PMID: 25892092

9

Astragaloside IV suppresses transforming growth factor-β1 induced fibrosis of cultured mouse renal fibroblasts via inhibition of the MAPK and NF-κB signaling pathways.

Che X, Wang Q, Xie Y, Xu W, Shao X, Mou S, Ni Z. Che X, et al. Among authors: shao x. Biochem Biophys Res Commun. 2015 Sep 4;464(4):1260-1266. doi: 10.1016/j.bbrc.2015.07.116. Epub 2015 Jul 26. Biochem Biophys Res Commun. 2015. PMID: 26220342

10

Up-regulation of Serum MiR-130b-3p Level is Associated with Renal Damage in Early Lupus Nephritis.

Wang W, Mou S, Wang L, Zhang M, Shao X, Fang W, Lu R, Qi C, Fan Z, Cao Q, Wang Q, Fang Y, Ni Z. Wang W, et al. Among authors: shao x. Sci Rep. 2015 Aug 28;5:12644. doi: 10.1038/srep12644. Sci Rep. 2015. PMID: 26316103 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,787 results

Search Page

Filters